These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 16123912

  • 1. Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
    Wolzt M, Sarich TS, Eriksson UG.
    Semin Vasc Med; 2005 Aug; 5(3):254-8. PubMed ID: 16123912
    [Abstract] [Full Text] [Related]

  • 2. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
    Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska M, Larsson M, Eriksson UG.
    Clin Pharmacokinet; 2003 Aug; 42(8):765-77. PubMed ID: 12846597
    [Abstract] [Full Text] [Related]

  • 3. No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran.
    Sarich TC, Schützer KM, Dorani H, Wall U, Kalies I, Ohlsson L, Eriksson UG.
    J Clin Pharmacol; 2004 Aug; 44(8):928-34. PubMed ID: 15286097
    [Abstract] [Full Text] [Related]

  • 4. No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers.
    Sarich TC, Schützer KM, Wollbratt M, Wall U, Kessler E, Eriksson UG.
    J Clin Pharmacol; 2004 Aug; 44(8):935-41. PubMed ID: 15286098
    [Abstract] [Full Text] [Related]

  • 5. A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor.
    Teng R, Sarich TC, Eriksson UG, Hamer JE, Gillette S, Schützer KM, Carlson GF, Kowey PR.
    J Clin Pharmacol; 2004 Sep; 44(9):1063-71. PubMed ID: 15317834
    [Abstract] [Full Text] [Related]

  • 6. Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion.
    Eriksson UG, Dorani H, Karlsson J, Fritsch H, Hoffmann KJ, Olsson L, Sarich TC, Wall U, Schützer KM.
    Drug Metab Dispos; 2006 May; 34(5):775-82. PubMed ID: 16455803
    [Abstract] [Full Text] [Related]

  • 7. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers.
    Dorani H, Schützer KM, Sarich TC, Wall U, Logren U, Ohlsson L, Eriksson UG.
    Eur J Clin Pharmacol; 2007 Jun; 63(6):571-81. PubMed ID: 17387462
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and pharmacodynamics of ximelagatran.
    Wolzt M, Sarich TS, Eriksson UG.
    Semin Vasc Med; 2005 Aug; 5(3):245-53. PubMed ID: 16123911
    [Abstract] [Full Text] [Related]

  • 10. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K, Eriksson-Lepkowska M, Frison L, Fager G, Eriksson UG.
    Clin Pharmacokinet; 2003 Aug; 42(8):755-64. PubMed ID: 12846596
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL.
    J Am Coll Cardiol; 2005 Jan 04; 45(1):1-9. PubMed ID: 15629364
    [Abstract] [Full Text] [Related]

  • 13. The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol.
    Sarich TC, Johansson S, Schützer KM, Wall U, Kessler E, Teng R, Eriksson UG.
    J Clin Pharmacol; 2004 Apr 04; 44(4):388-93. PubMed ID: 15051746
    [Abstract] [Full Text] [Related]

  • 14. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, Eriksson UG.
    Clin Pharmacokinet; 2003 Apr 04; 42(4):381-92. PubMed ID: 12648028
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
    Fager G, Cullberg M, Eriksson-Lepkowska M, Frison L, Eriksson UG.
    Eur J Clin Pharmacol; 2003 Aug 04; 59(4):283-9. PubMed ID: 12845508
    [Abstract] [Full Text] [Related]

  • 18. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
    Eriksson UG, Johansson S, Attman PO, Mulec H, Frison L, Fager G, Samuelsson O.
    Clin Pharmacokinet; 2003 Aug 04; 42(8):743-53. PubMed ID: 12846595
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC, Perry CM, Faulds D.
    Drugs; 2004 Aug 04; 64(6):649-78. PubMed ID: 15018597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.